News|Articles|February 13, 2019

Talzenna for gBRCAm HER2-negative Locally Advanced or Metastatic Breast Cancer

Author(s)Drew Boxler

Talzenna (talazoparib, Pfizer)

Indications: Adult Patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) HER2-negative locally advanced or metastatic breast cancer.

Dosage: 1 mg singly oral daily dose until disease progression or unacceptable toxicity occurs

Contraindications: None

Click here for more prescribing information

Newsletter

Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.


Latest CME